To Investigate the Role of Upstream High Dose Statin in STEMI
Status: | Completed |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 25 - 90 |
Updated: | 10/7/2018 |
Start Date: | June 2009 |
End Date: | June 2010 |
A Double Blinded Randomized Placebo Controlled Study: To Investigate the Role of Upstream High Dose Statin Treatment in Patients With ST Segment Elevation Myocardial Infarction
This is a double-blinded randomized placebo controlled trial investigating the role of
upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for
acute STEMI.
upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for
acute STEMI.
Inclusion Criteria:
1. Any patient of 25 to 90 years of age admitted or transferred to Western Pennsylvania
Hospital or Allegheny General Hospital with a diagnosis of STEMI undergoing emergent
percutaneous intervention (PCI) to the culprit coronary artery. STEMI is defined as
greater than 1mm ST segment elevation on electrocardiogram.
2. Elevated cardiac biomarkers (troponin-T > 0.03ng/ml, CKMB>5ng/mL, or ck>170 U/l).
Exclusion Criteria:
1. Known history of liver disease defined as cirrhosis, alcoholic liver disease, Non
alcoholic steatohepatitis, hepatitis or any causes of liver failure.
2. Renal failure with creatinine >3mg/dL
3. Known history of liver or muscle disease such as rheumatologic myopathies, history of
myositis, hepatitis, and hepatic cancer.
4. Cardiovascular arrest and shock.
We found this trial at
2
sites
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
Click here to add this to my saved trials
Western Pennsylvania Hospital Featuring 308 private patient beds, West Penn Hospital has served Bloomfield and...
Click here to add this to my saved trials